Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease. U.S. Safety Officials Urge Boeing, ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...